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E-mail address: lara.al-khoury@hotmail.com (L.A.-Surgical removal of the insulinoma continues to be the treatment of choice. Medical therapy should be
considered in patients who cannot undergo surgery. We are reporting our experience with regard to
the efﬁcacy of Diphenylhydantoin (DPH) in controlling hypoglycemia and suppressing insulin release
in patients with insulinomas. DPH was administered orally at a dose of 300–400 mg/day to three patients
with documented endogenous insulin excess. The ﬁrst two patients received the drug temporarily during
the preoperative period, with resolution of the hypoglycemic attacks, normalization of blood glucose, and
reduction of insulin levels. Subsequent surgery conﬁrmed the presence of insulin-secreting pancreatic
tumor. Cure was achieved after excision of the tumor. The third patient represented a diagnostic and
threrapeutic challenge. An insulin-secreting tumor located in the body of the pancreas was diagnosed
in a patient with type 2 diabetes and end stage renal disease. The patient’s poor cardiac function contra-
indicated surgery. DPH resulted in an excellent sustained control of his blood sugar and a fall in insulin
levels for several months. We believe that DPH is a potent inhibitor of insulin secretion and, thus, is suit-
able as a temporary therapeutic measure in the preoperative period of patients with insulinoma, as well
as an alternative to surgery for those who are not surgical candidates.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Since its ﬁrst description in the early 1920s, surgical removal of
insulinoma is the treatment of choice [1–3]. Medical therapy
should be considered for patients with insulinomas missed during
pancreatic exploration, and for patients who refuse surgery or have
inoperable/metastatic disease. We are reporting here three pa-
tients with insulinoma in whom diphenylhydantoin (DPH) was
effective in suppressing insulin release and preventing hypoglyce-
mia. A brief review is made of the properties of DPH as an insulin-
suppressing agent.
2. Patients and results
2.1. Patient 1
Patient 1 was a 31-year-old male who presented with recurrent
nocturnal seizures. Among a variety of antiepileptic drugs, he re-
sponded best to DPH. Further investigations led to the ﬁnal diagno-
sis of hypoglycemia-induced seizures and imaging revealed a
tumor in the pancreatic body. Pre-operatively, treatment with
DPHwas able to correct the hypoglycemia and thus prevent the sei-
zures. A benign insulinoma was successfully removed and the pa-
tient was cured and became free of hypoglycemia and of seizures.ellitus. Published by Elsevier Ltd. O
; fax: +961 1 370814.
K. Nabbout).2.2. Patient 2
Patient 2 was a 26 year old female who had a one year history of
fasting hypoglycemic episodes and weight gain. Laboratory evalu-
ation showed a low fasting serum glucose level (2.72 mmol/l) with
simultaneously elevated serum insulin (30.6 lU/ml) and C-peptide
(2 ng/ml) levels. Complete blood count, renal and liver function
tests, serum TSH, cortisol and GH levels were all normal. Endo-
scopic Ultra Sound (EUS) showed a 2  2 cm tumor in the tail of
the pancreas. Before undergoing a distal pancreatectomy four days
later, DPH (400 mg/d) resulted in a fall in insulin levels and a rise in
fasting glucose levels (Table 1) and allowed discontinuation of
intravenous dextrose infusion. Pathology revealed a benign insuli-
noma and post-operatively, the patient became totally free of
hypoglycemic episodes.
2.3. Patient 3
Patient 3 was a 65-year-old male a known case of previously
poorly controlled type 2 diabetes. After 15 years he had ended with
end-stage renal disease, requiring chronic hemodialysis. In the pre-
ceding year while on hemodialysis, he became euglycemic, even
without insulin treatment, and thereafter started having recurrent
fasting hypoglycemia with documented endogenous insulin ex-
cess. EUS revealed a 2  2 cm lesion in the body of the pancreas.
As he was not a surgical candidate due to advanced coronary artery
disease, medical treatment for insulinoma had to be a substitutepen access under CC BY-NC-ND license.
Table 1
Effect of DPH on serum glucose and insulin levels in case 2.
Before DPH After DPH
Fasting serum glucose mmol/l
(reference range)
2.72 (3.33–5.55) 3.33 (3.33–5.55)
Fasting serum insulin lU/ml
(reference range)
30.6 (4.0–25.0) 20.0 (4.0–25.0)
Table 2
Effect of DPH on serum glucose and insulin levels in case 3.
Before DPH After DPH
Fasting serum glucose mmol/l
(reference range)
2.71 (3.33–5.55) 6.66 (3.33–5.55)
Fasting serum insulin lU/ml
(reference range)
82.0 (4.0–25.0) 31.7 (4.0–25.0)
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sustained control of his serum glucose and a fall in insulin levels
(Table 2). Since the past 20 months the patient is still maintained
on DPH and no hypoglycemic episodes.
3. Discussion
In the cases presented above, DPH was effective in controlling
hypoglycemia in three patients with insulinoma, either temporar-
ily in the preoperative period or as an alternative to surgery. In hu-
mans and in animals DPH has been shown to cause hyperglycemia.
The intraperitoneal injection of DPH in rabbits [4] and the intrave-
nous administration of DPH in dogs [5] produced a marked in-
crease in blood glucose levels. These observations were soon
followed by the clinical recognition of hyperglycemia and even
hyperglycemic non-ketotic coma after administration of DPH in
humans [6–8].MORE ABOUT THIS STUDY
Due to the advances in localization techniques and the high
surgical success rates, the medical treatment of insulinomas
has been a neglected topic in the last three decades. How-
ever, the use of agents that suppress insulin release should
not be considered only as an alternative to surgery, but also
as a temporary measure in the preoperative period.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC
When surgery fails or cannot be undertaken in a patient with
documented endogenous insulin excess, medical measures
to suppress insulin releases become a life-saving necessity.
Among the agents used in the literature are Diazoxide,
Somatostatin analogue (Octreotide), Diphenylhydantoin,
Glucocorticoids, Glucagon, Calcium channel blockers, and
Beta blockers.
WHAT THIS STUDY ADDS
Although Diazoxide is the most widely used drug in the med-
ical treatment of insulinoma, several lines of evidence sug-
gest that, through its ability to affect both the provision and
release of insulin, Diphenylhydantoin has a broader action
than Diazoxide and, thus, offers a better control of
hypoglycemia.
The mechanism by which DPH causes hyperglycemia is be-
lieved to be impaired insulin release. This hypothesis was ﬁrst sug-
gested by Peters and Samaan [9] who reported a delayed and
subnormal insulin response to glucose administration when the
serum concentration of DPH was at toxic levels. Later on, the inhi-
bition of insulin released by DPH was conﬁrmed using the isolatedperfused rat pancreas [10]. In humans, several studies have shown
that oral administration of DPH results in a higher blood glucose
response and diminution of the early and late post-prandial insulin
responses [11]. All the above observations, and others [12–14] lead
to the conclusion that, at blood levels similar to those attained in
the treatment of epilepsy, DPH is a potent inhibitor of insulin
release.
The mechanism of the inhibitory effect of DPH on glucose-in-
duced insulin release has also been studied, using isolated pancre-
atic islet cells. DPH causes hyper-polarization of the plasma
membrane in islet cells; an effect that could be brought about by
the stimulatory effect of DPH on the membrane sodium–potas-
sium–magnesium ATPase-related pump [15–17], which reduces
the uptake of sodium by the islets. Optimal sodium concentration
is necessary for insulin secretion [18]. Thus, it seems possible that
the effects on cellular sodium are, in part, involved in the inhibitory
mechanism of DPH. This pump system, in turn, may inﬂuence cal-
cium uptake, an initial requirement for insulin secretion [19]. Fur-
thermore, DPH has also been shown to block calcium uptake via
voltage dependent calcium channels [20]. In addition, it also de-
creases calcium efﬁcacy in the exocytotic system [21]. Peripheral
inhibition of the action of insulin by DPH is another possible, but
less conﬁrmed, explanation for the DPH-induced hyperglycemia
in vivo.
Another well-known effect of DPH is the inhibition of glucagon
secretion in vitro [22] and in humans [23]. Due to its inhibitory ef-
fect on insulin release, we and others have used DPH to temporar-
ily control hyperglycemia during the preoperative period in
patients with insulinoma [24–26]. It has also been used in the
treatment of hypoglycemia induced by inoperable insulinomas
[27]. The advantages of DPH over Diazoxide, the most widely used
drug in the medical treatment of insulinoma, were studied [28].
From the experimental observations of the perfused rat pancreas,
it is known that insulin is stored in a labile compartment that is
concentration-related to a larger and more stable storage compart-
ment containing 98% of total b cell insulin [29]. And it is currently
accepted that pancreatic insulin secretion is biphasic and involves
the immediate release from the small labile pool followed by the
subsequent provision of insulin to this labile pool from the larger
storage compartment [30]. When Levin et al. [28] compared DPH
and Diazoxide with respect to their effects upon insulin secretion
by the isolated perfused rat pancreas, it was found that DPH inhib-
its both secretion from the labile insulin compartment and provi-
sion of insulin and/or precursors to this compartment, whereas
Diazoxide inhibits insulin release from the labile pool, but contin-
ues to allow insulin to be provided by the larger storage compart-
ment. This was translated into constant levels of inhibition by DPH
during infusion of the agent, without escape, and without post-
inhibitory overshoot, whereas with Diazoxide, although there
was an initial fall in secretion, this was followed by an escape to-
wards a pre-inhibition level followed by a post-inhibitory over-
shoot. Furthermore, Kizer et al. [31] showed that inhibition of
insulin secretion by DPH could not be overcome by Tolbutamide,
whereas Diazoxide inhibition can be reversed by Tolbutamide
[32]. Thus, it is justiﬁable to state that DPH is advantageous over
Diazoxide to blockade insulin release. Fariss and Lutcher [33] de-
ﬁned the optimal dose of DPH required for insulin suppression
when they found that in response to oral glucose, the blood glucose
levels were within the limits of normal with doses of DPH of 100,
200, 300 mg/d but not with 400 mg/d. The insulin response was
further delayed with each increase of DPH to the point where there
was little or no further effect during the test period of 400 mg dos-
age. Therefore, a 400 mg/d of DPH is recommended for adequate
suppression of insulin secretion. Finally, our third patient repre-
sented a very challenging case in which an insulinoma was
diagnosed in a type 2 diabetic patient. Very few similar cases have
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40]. The clinical implication is that the presence of an insulin-
secreting tumor should be considered in a diabetic patient who
presents with an otherwise unexplained hypoglycemia.
4. Conclusion
Based on the above facts, we suggest that DPH is suitable as a
temporary therapeutic measure in the preoperative period of pa-
tients with insulinoma, as well as an alternative to surgery for
those who are not surgical candidates.
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